Drugs / ACT-1014-6470
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05123820 | Nov 2021 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04899219 | Jun → Nov 2021 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04608513 | Nov 2020 → Sep 2021 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04183686 | Nov 2019 → Mar 2020 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-1014-6470 | “ACT-1014-6470 soft capsule for oral administration.” NCT05123820 ↗ |
| Route | Oral | “soft capsules for oral use” NCT04183686 ↗ |